Viral intra-host evolution in immunocompetent children contributes to human norovirus diversification at the global scale.


Journal

Emerging microbes & infections
ISSN: 2222-1751
Titre abrégé: Emerg Microbes Infect
Pays: United States
ID NLM: 101594885

Informations de publication

Date de publication:
Dec 2021
Historique:
pubmed: 12 8 2021
medline: 24 12 2021
entrez: 11 8 2021
Statut: ppublish

Résumé

Norovirus is a major cause of acute gastroenteritis. Human noroviruses present >30 different genotypes, with a single genotype (GII.4) predominating worldwide. Concurrent outbreaks of norovirus are often associated with the emergence of new viruses. While different hypotheses have been presented, the source of new mutations in noroviruses is still unknown. In this study, we applied high-resolution sequencing to determine the intra-host viral diversity presented by noroviruses during the acute and shedding phase of infection in children. Profiling viral intra-host diversification at nearly full genome level indicated that GII.4 viruses presented dynamic intra-host variation, while non-GII.4 viruses presented minimal variation throughout the infection. Notably, the intra-host genetic variation during the shedding phase recapitulates the genetic diversity observed at the global level, particularly those mapping at the VP1 antigenic sites. Thus the intra-host evolution in healthy children explains the source of norovirus mutations that results in diversification at the global scale.

Identifiants

pubmed: 34376124
doi: 10.1080/22221751.2021.1967706
pmc: PMC8425682
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1717-1730

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI108695
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI099737
Pays : United States

Références

mSphere. 2017 Mar 29;2(2):
pubmed: 28405629
J Clin Microbiol. 2003 Apr;41(4):1548-57
pubmed: 12682144
J Gen Virol. 2019 Oct;100(10):1393-1406
pubmed: 31483239
Emerg Infect Dis. 2005 Jul;11(7):1079-85
pubmed: 16022784
J Infect Dis. 2022 Apr 1;225(7):1205-1214
pubmed: 32179892
J Virol. 2019 Dec 12;94(1):
pubmed: 31619551
Epidemiol Infect. 2015 Jun;143(8):1710-7
pubmed: 25336060
Nature. 2015 Jul 9;523(7559):217-20
pubmed: 26053121
J Gen Virol. 2018 Aug;99(8):1027-1035
pubmed: 29916802
PLoS Pathog. 2021 Jul 13;17(7):e1009744
pubmed: 34255807
J Virol. 2015 Jun;89(11):5756-9
pubmed: 25787285
J Virol. 2020 Feb 14;94(5):
pubmed: 31801858
Virus Evol. 2019 Nov 25;5(2):vez048
pubmed: 32161666
PLoS Pathog. 2012;8(5):e1002705
pubmed: 22615565
Virology. 1988 Mar;163(1):112-22
pubmed: 3267218
Elife. 2018 May 03;7:
pubmed: 29683424
J Infect Dis. 2008 Oct 1;198(7):994-1001
pubmed: 18774885
Lancet Infect Dis. 2018 May;18(5):545-553
pubmed: 29396001
J Clin Virol. 2011 Jun;51(2):121-5
pubmed: 21514213
Elife. 2017 Jun 27;6:
pubmed: 28653624
Viruses. 2020 Nov 10;12(11):
pubmed: 33182775
J Virol. 2003 Nov;77(21):11603-15
pubmed: 14557646
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
Front Microbiol. 2017 Jan 31;8:73
pubmed: 28197136
Science. 1999 Oct 8;286(5438):287-90
pubmed: 10514371
PLoS Pathog. 2010 Mar 26;6(3):e1000831
pubmed: 20360972
J Virol. 2013 Mar;87(5):2803-13
pubmed: 23269783
Clin Infect Dis. 2014 Feb;58(4):483-91
pubmed: 24300042
J Virol. 2012 Mar;86(6):3219-29
pubmed: 22205753
Cell Host Microbe. 2021 Jan 13;29(1):32-43.e4
pubmed: 33212020
Viruses. 2019 May 25;11(5):
pubmed: 31130647
mSphere. 2017 May 17;2(3):
pubmed: 28529975
Clin Infect Dis. 2021 Jun 1;72(11):e806-e814
pubmed: 33033835
Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):
pubmed: 33836574
J Virol. 2021 Jan 13;95(3):
pubmed: 33115870
Virus Evol. 2017 Jul 28;3(2):vex018
pubmed: 28775894
Euro Surveill. 2017 Jan 26;22(4):
pubmed: 28181902
J Infect Dis. 1995 Mar;171(3):566-9
pubmed: 7876602
J Virol Methods. 2016 Aug;234:54-64
pubmed: 27033182
Genome Biol. 2019 Jan 8;20(1):8
pubmed: 30621750
Immunity. 2019 Jun 18;50(6):1530-1541.e8
pubmed: 31216462
Database (Oxford). 2016 Mar 17;2016:
pubmed: 26989153
BMC Genomics. 2016 Jul 01;17:480
pubmed: 27363999
J Virol. 2014 Dec;88(24):14184-96
pubmed: 25275120
J Infect Dis. 2017 Dec 19;216(12):1513-1524
pubmed: 29029115
mBio. 2019 Sep 24;10(5):
pubmed: 31551337
Syst Biol. 2010 May;59(3):307-21
pubmed: 20525638
PLoS Pathog. 2017 Jan 19;13(1):e1006136
pubmed: 28103318
Virus Evol. 2020 Feb 17;6(1):veaa010
pubmed: 32082616
Viruses. 2019 Mar 01;11(3):
pubmed: 30823663
J Virol. 2019 Feb 19;93(5):
pubmed: 30541855

Auteurs

Kentaro Tohma (K)

Division of Viral Products, CBER, FDA, Silver Spring, MD, USA.

Mayuko Saito (M)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Monica J Pajuelo (MJ)

Department of Cellular and Molecular Sciences, Faculty of Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru.

Holger Mayta (H)

Department of Cellular and Molecular Sciences, Faculty of Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru.

Mirko Zimic (M)

Department of Cellular and Molecular Sciences, Faculty of Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru.

Cara J Lepore (CJ)

Division of Viral Products, CBER, FDA, Silver Spring, MD, USA.

Lauren A Ford-Siltz (LA)

Division of Viral Products, CBER, FDA, Silver Spring, MD, USA.

Robert H Gilman (RH)

Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.

Gabriel I Parra (GI)

Division of Viral Products, CBER, FDA, Silver Spring, MD, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH